HDAC9 and cancer: The utility of FDA-approved drugs, such as vorinostat, romidepsin, belinostat, and panobinostat, along with the challenges remaining concerning the use of these HDAC inhibitors for cancer treatment, have encouraged the design and synthesis of new compounds as selective HDAC inhibitors [127].